Operating
Change in AR
Alnylam Pharmaceuticals Change in AR decreased by 72.4% to $110.42M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 1385.4%, from $7.43M to $110.42M. Over 2 years (FY 2021 to FY 2024), Change in AR shows a downward trend with a -9.4% CAGR.
Analysis
StatementCash Flow Statement
SectionOperating
First reportedQ1 2016
Last reportedQ1 2026Apr 30, 2026
Metric ID:
change_in_accounts_receivableHistorical Data
17 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $35.31M | $0.00 | $59.45M | -$39.70M | -$6.40M | $38.42M | $53.27M | -$19.15M | $107.99M | -$410.00K | -$9.64M | $37.09M | $59.51M | $7.43M | $136.91M | $399.86M | $110.42M |
| QoQ Change | — | -100.0% | — | -166.8% | +83.9% | +700.5% | +38.6% | -136.0% | +663.8% | -100.4% | <-999% | +484.8% | +60.4% | -87.5% | >999% | +192.1% | -72.4% |
| YoY Change | — | — | — | — | -118.1% | — | -10.4% | +51.8% | +181.1% | +97.9% | — | -65.7% | — | >999% | >999% | +978.0% | >999% |
Range-$39.70M – $399.86M
CAGR+33.0%
Avg YoY Growth+593.3%
Median YoY Growth+139.5%
Change in AR at Other Companies
Frequently Asked Questions
- What is Alnylam Pharmaceuticals's change in ar?
- Alnylam Pharmaceuticals (ALNY) reported change in ar of $110.42M in Q1 2026.
- How has Alnylam Pharmaceuticals's change in ar changed year-over-year?
- Alnylam Pharmaceuticals's change in ar increased by 1385.4% year-over-year, from $7.43M to $110.42M.
- What is the long-term trend for Alnylam Pharmaceuticals's change in ar?
- Over 2 years (2021 to 2024), Alnylam Pharmaceuticals's change in ar has grown at a -9.4% compound annual growth rate (CAGR), from $105.47M to $86.55M.